1,721,149 research outputs found
Immunomodulators and enzymes of purine metabolism in human lymphocytes. Ambrogi F, Petrini M, Azzara A, Carulli G, Caracciolo F, Grassi B, Bertelli A.
No full textThe enzymes ADA and PNP were evaluated in lymphocytic subpopulations in peripheral blood obtained from healthy subjects, elderly subjects and patients with immunoproliferative diseases. Some similar assessments were performed on lymphoid cells from cord blood. Preliminary studies indicate that Thymostimulin can in some cases correct enzymic defects
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
L-PROPIONYL CARNITINE PROTECTS ERYTHROCYTES AND LOW-DENSITY LIPOPROTEINS AGAINST PEROXIDATION
No full textThe effects of peroxidation on the erythrocytes of rats orally treated with L-propionyl carnitine for 15 day) (50 mg/kg/day/ were investigated. Peroxidation was produced by incubating the cells in the presence of the cytotoxic system: lactoperoxidase-hydrogen peroxide and iodide ions. Lysis of erythrocytes was evaluated by measuring the turbidity following the decrease in absorbance at 600 nm. The 50% of erythrocyte lysis of untreated animals was observed after 16 min and in about 30 min all the cells were lysed. With L-propionyl carnitine-treated rat erythrocytes the time at which 50% of lysis was observed increased to 23 min. L-propionyl carnitine also exerted its protective effect in vitro when incubated with untreated rat erythrocytes or human erythrocytes in the presence of the cytolytic system. The presence of L-propionyl carnitine in the incubation mixture markedly decreased the malonaldehyde formation. The protection was concentration-dependent. To establish if L-propionyl carnitine protects from oxygen reactive species or is able to stabilize the damaged membranes, a latent damage was produced by incubating the erythrocytes with the cytolytic system for a few minutes. The cells were then removed and suspended in buffered saline in the absence or in the presence of different L-propionyl carnitine concentrations L-propionyl carnitine decreased the velocity of lysis of damaged erythrocytes. These data suggest that L-propionyl carnitine protects erythrocytes from oxygen reactive species and also stabilizes the damaged membrane probably by specific binding with protein and/or phospholipid domains. Low density lipoproteins (LDLs) from human blood were peroxidized by exposure to Cu2+ ions in the presence of various L-propionyl carnitine concentrations. The formation of malonaldehyde decreased in the presence of L-propionyl carnitine, These findings provide evidence that L-propionyl carnitine protects cell membrane and circulating lipoproteins from peroxidation and stabilizes the cell membrane damaged by oxygen reactive species
Calcium antagonists: accounts on new perspectives of their use and an update on side effects
No full textAlthough calcium antagonists are drugs which have been introduced relatively recently, their use is already so widespread, at least in the treatment of cardiovascular diseases as to represent one of the main therapies for diseases such as ischaemic cardiopathy, arterial hypertension, and, to a lesser extent, arrhythmias. Together with the development of clinical applications, deeper insight has been gained into the clinical and experimental pharmacology of these drugs. The authors of this review concentrate their attention on some of the less frequently discussed aspects of calcium antagonists. On the one hand, they describe some "nonprimary" uses of these drugs, both in the cardiovascular and in other therapeutic fields, which already receive confirmation from relatively solid experimental data. On the other hand, they review the side effects and some pharmacological interactions of calcium antagonists, both of which should be held in due consideration, seeing that these drugs are widely employed in clinical practice and their use often requires prolonged, intensive treatment. The most common side effects are described, together with others relatively less well known ones, and outline is given of potential undesirable effects on the cardiovascular as well as on other systems
The potentiating effect of propionyl carnitine on prostacycline prevention of thrombosis induced by endothelin (ET-1) and K-carrageenin
No full text- …
